公开(公告)号：US20210017206A1

公开(公告)日：2021-01-21

申请号：US16980473

申请日：2019-03-14

Applicant: Pfizer Inc.

Inventor： Matthew Frank Brown ,  Ye Che ,  Anthony Marfat ,  Michael Joseph Melnick ,  Justin Ian Montgomery ,  Timothy Allan Johnson ,  Richard Andrew Ewin ,  Daniel Paul Uccello ,  Usa Reilly ,  Tamim Fehme Braish

IPC: C07F9/6558 ,  C07F9/58 ,  C07F5/04 ,  A61P31/04

Abstract: The present invention is directed to new pyridinone or pyrimidinone hydroxamic acid phosphates of Formula (1) and boronates of Formula (2), stereoisomers thereof; wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O−M+), —P(O)(O−M+)2 and —P(O)(O−)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation; X is CH or N; and Z is as defined herein; and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

公开(公告)号：US20210017205A1

公开(公告)日：2021-01-21

申请号：US16980616

申请日：2019-03-14

Applicant: Pfizer Inc.

Inventor： Tamim Fehme Braish ,  Matthew Frank Brown ,  Ye Che ,  Richard Andrew Ewin ,  Timothy Allan Johnson ,  Michael Joseph Melnick ,  Justin Ian Montgomery ,  Mark Stephen Plummer ,  Loren Michael Price ,  Usa Reilly ,  Daniel Uccello

IPC: C07F9/58 ,  C07F5/02 ,  A61P31/04

Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O−M+), —P(O)(O−M+)2 and —P(O)(O−)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

公开(公告)号：US09950058B2

公开(公告)日：2018-04-24

申请号：US15385611

申请日：2016-12-20

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  C07K14/135 ,  C12N15/01 ,  C07K14/005 ,  C12N7/00 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K2039/575 ,  C07K14/005 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/70 ,  C07K2319/735 ,  C12N7/00 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US20240100153A1

公开(公告)日：2024-03-28

申请号：US18506578

申请日：2023-11-10

Applicant: Pfizer Inc.

Inventor： Yuhang Liu ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Philip Ralph Dormitzer ,  Jennifer Anne Nicki ,  Xiaojie Yao

IPC: A61K39/245 ,  C07K14/045 ,  C12N7/00

CPC classification number: A61K39/245 ,  C07K14/045 ,  C12N7/00 ,  C12N2710/16134

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

公开(公告)号：US20220088184A1

公开(公告)日：2022-03-24

申请号：US17350008

申请日：2021-06-17

Applicant: Pfizer Inc.

Inventor： Yuhang Liu ,  Ye Che ,  Xiaoyuan Sherry Chi ,  Philip Ralph Dormitzer ,  Jennifer Anne Nicki ,  Xiaojie Yao

IPC: A61K39/245 ,  C07K14/045 ,  C12N7/00

Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

公开(公告)号：US20210023200A1

公开(公告)日：2021-01-28

申请号：US17060944

申请日：2020-10-01

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US10238732B2

公开(公告)日：2019-03-26

申请号：US15896871

申请日：2018-02-14

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  C07K14/135 ,  C12N15/01 ,  C07K14/005 ,  C12N7/00 ,  A61K39/12 ,  A61K39/00

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US20180177864A1

公开(公告)日：2018-06-28

申请号：US15896871

申请日：2018-02-14

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  A61K39/12

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K2039/575 ,  C07K14/005 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/70 ,  C07K2319/735 ,  C12N7/00 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US20170247372A1

公开(公告)日：2017-08-31

申请号：US15446500

申请日：2017-03-01

Applicant: Pfizer Inc.

Inventor： Atli Thorarensen ,  Matthew Frank Brown ,  Agustin Casimiro-Garcia ,  Ye Che ,  Jotham Wadsworth Coe ,  Mark Edward Flanagan ,  Adam Matthew Gilbert ,  Matthew Merrill Hayward ,  Jonathan David Langille ,  Justin Ian Montgomery ,  Jean-Baptiste Telliez ,  Rayomand Jal Unwalla ,  John I. Trujillo

IPC: C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D471/08 ,  C07D498/04

CPC classification number: C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04

Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

公开(公告)号：US09617258B2

公开(公告)日：2017-04-11

申请号：US14559294

申请日：2014-12-03

Applicant: Pfizer Inc.

Inventor： Atli Thorarensen ,  Matthew Frank Brown ,  Agustin Casimiro-Garcia ,  Ye Che ,  Jotham Wadsworth Coe ,  Mark Edward Flanagan ,  Adam Matthew Gilbert ,  Matthew Merrill Hayward ,  Jonathan David Langille ,  Justin Ian Montgomery ,  Jean-Baptiste Telliez ,  Rayomand Jal Unwalla ,  John I. Trujillo

IPC: A61K31/519 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04

CPC classification number: C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/10 ,  C07D498/04

Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof, having the structure: or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.